Progress continues on the ABC2-funded immunotherapy research by Catherine Flores and her team at UF.
Guest blogger Shawn Peters shares why he's running the 2015 Marine Corps Marathon to support ABC2.
These studies provide a foundational rationale for ABC2's efforts in the profiling space.
An ABC2-funded brain cancer vaccine receives positive reviews at the American Society of Clinical Oncology Annual Meeting.
Our deepest sympathies go out to his friends and family.
BethAnn Telford, a brain cancer survivor and Ironman athlete, is the inspiration behind the company’s summer hotel promotion.
We welcome the newest member of our team. Kathleen brings a wealth of major and corporate gift development experience.
ABC2 was an early investor in this pioneering research.
Proceeds from the Florida Brain Cancer 5k support this ongoing partnership.
ABC2 is working with Matt de Silva, co-founder of Notable Labs, to advance personalized treatments for brain cancer.
He plans to build another world-class brain tumor center and our team at ABC2 looks forward to working with him.
ABC2 is funding the whole exome sequencing of NeoVax tumors at the Broad Institute to assist Dana-Farber researchers.
Karin Mallory is taking action after her father's brain cancer diagnosis. She's producing The Steel Wheels Benefit Concert for ABC2. It will be streamed live via “Concert Window” on March 28th.
An interview with Max Wallace, CEO of Accelerate Brain Cancer Cure.
Max Wallace, CEO of ABC², responds to the op-ed piece by Llewellyn Hinkes-Jones published this week in the New York Times.
Concert proceeds benefit Accelerate Brain Cancer Cure.
ABC2-funded research in the news and a blog post by Al Musella, of the Musella Foundation, about Novocure's promising Optune trial results.
Accelerate Brain Cancer Cure funded Duke University's early work on the vaccine.
Proceeds to benefit Accelerate Brain Cancer Cure.
Second Brain Tumor Clinical Trial Endpoints Workshop identified steps needed to include measures of patient signs, symptoms, and function as part of evaluation of therapy benefit.
ABC2 CEO Max Wallace chaired the gathering of NCI experts and cancer advocates.
Principal Investigators, based in the state of Florida, are invited to apply. Proposal deadline: December 15, 2014.
ABC2 funds project between UC San Diego Health System and Regulus Therapeutics Inc.